Vol.56 No.S-1 April 2008
Clinical study of sitafloxacin in febrile complicated pyelonephritis
1)Gifu University School of Medicine, 1-1 Yanagido, Gifu, Japan
2)Department of Urology, Kizawa Memorial Hospital
3)Department of Urology, Kobe Red Cross Hospital
4)Department of Urology, Okayama Citizens' Hospital
5)Department of Urology, University of Occupational and Environmental Health
Abstract
The clinical efficacy and safety of sitafloxacin(STFX), a fluoroquinolone compound, were evaluated in patients with febrile complicated pyelonephritis treated orally 7 days with 100 mg b.i.d. of STFX. Clinical efficacy was evaluated at 3, 7, and 14 days based on criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection (third edition).
Overall clinical efficacy at 7 days was 100% (20/20), at 3 days was 100% (20/20), and at 14 days was 64.3% (9/14). Among the 36 isolates before dosing, overall microbiological eradication was 100% (36/36) at 7 days. The incidence of adverse reactions was 45.5% (10/22), the most common of which were diarrhea and alanine aminotransferase increase. All symptoms were mild. Results suggest that STFX is a useful antibacterial agent in the treatment of febrile complicated pyelonephritis.
Key word
sitafloxacin, febrile complicated pyelonephritis, clinical trial
Received
November 2, 2007
Accepted
December 18, 2007
Jpn. J. Chemother. 56 (S-1): 103-109, 2008
